vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and RPC INC (RES). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $425.8M, roughly 1.7× RPC INC). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs -0.7%, a 11.5% gap on every dollar of revenue. On growth, RPC INC posted the faster year-over-year revenue change (27.0% vs 3.9%). Over the past eight quarters, RPC INC's revenue compounded faster (6.2% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

RPC Group plc is based in the United Kingdom, and is one of Europe's largest supplier of plastic packaging. Its headquarters are in Rushden in Northamptonshire. It was listed on the London Stock Exchange until it was acquired in 2019 by Berry Global Group Inc, which in turn was acquired by Amcor in 2025.

AMRX vs RES — Head-to-Head

Bigger by revenue
AMRX
AMRX
1.7× larger
AMRX
$722.5M
$425.8M
RES
Growing faster (revenue YoY)
RES
RES
+23.1% gap
RES
27.0%
3.9%
AMRX
Higher net margin
AMRX
AMRX
11.5% more per $
AMRX
10.8%
-0.7%
RES
Faster 2-yr revenue CAGR
RES
RES
Annualised
RES
6.2%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRX
AMRX
RES
RES
Revenue
$722.5M
$425.8M
Net Profit
$78.0M
$-3.1M
Gross Margin
44.3%
21.0%
Operating Margin
19.6%
-0.9%
Net Margin
10.8%
-0.7%
Revenue YoY
3.9%
27.0%
Net Profit YoY
410.5%
-124.0%
EPS (diluted)
$0.19
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
RES
RES
Q1 26
$722.5M
Q4 25
$814.3M
$425.8M
Q3 25
$784.5M
$447.1M
Q2 25
$724.5M
$420.8M
Q1 25
$695.4M
$332.9M
Q4 24
$730.5M
$335.4M
Q3 24
$702.5M
$337.7M
Q2 24
$701.8M
$364.2M
Net Profit
AMRX
AMRX
RES
RES
Q1 26
$78.0M
Q4 25
$35.1M
$-3.1M
Q3 25
$2.4M
$13.0M
Q2 25
$22.4M
$10.1M
Q1 25
$12.2M
$12.0M
Q4 24
$-31.1M
$12.8M
Q3 24
$-156.0K
$18.8M
Q2 24
$6.0M
$32.4M
Gross Margin
AMRX
AMRX
RES
RES
Q1 26
44.3%
Q4 25
36.5%
21.0%
Q3 25
34.9%
25.1%
Q2 25
39.5%
24.5%
Q1 25
36.8%
26.7%
Q4 24
36.0%
25.4%
Q3 24
38.4%
26.7%
Q2 24
35.6%
28.0%
Operating Margin
AMRX
AMRX
RES
RES
Q1 26
19.6%
Q4 25
13.8%
-0.9%
Q3 25
9.0%
4.7%
Q2 25
15.4%
3.7%
Q1 25
14.4%
3.7%
Q4 24
10.4%
3.1%
Q3 24
12.6%
5.7%
Q2 24
13.6%
9.7%
Net Margin
AMRX
AMRX
RES
RES
Q1 26
10.8%
Q4 25
4.3%
-0.7%
Q3 25
0.3%
2.9%
Q2 25
3.1%
2.4%
Q1 25
1.8%
3.6%
Q4 24
-4.3%
3.8%
Q3 24
-0.0%
5.6%
Q2 24
0.9%
8.9%
EPS (diluted)
AMRX
AMRX
RES
RES
Q1 26
$0.19
Q4 25
$0.10
$-0.02
Q3 25
$0.01
$0.06
Q2 25
$0.07
$0.05
Q1 25
$0.04
$0.06
Q4 24
$-0.10
$0.06
Q3 24
$0.00
$0.09
Q2 24
$0.02
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
RES
RES
Cash + ST InvestmentsLiquidity on hand
$197.7M
$210.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
Total Assets
$3.5B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
RES
RES
Q1 26
$197.7M
Q4 25
$282.0M
$210.0M
Q3 25
$201.2M
$163.5M
Q2 25
$71.5M
$162.1M
Q1 25
$59.2M
$326.7M
Q4 24
$110.6M
$326.0M
Q3 24
$74.0M
$276.9M
Q2 24
$43.8M
$261.5M
Total Debt
AMRX
AMRX
RES
RES
Q1 26
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
AMRX
AMRX
RES
RES
Q1 26
Q4 25
$-70.8M
$1.1B
Q3 25
$-109.5M
$1.1B
Q2 25
$-112.1M
$1.1B
Q1 25
$-131.7M
$1.1B
Q4 24
$-109.3M
$1.1B
Q3 24
$-93.4M
$1.1B
Q2 24
$-57.5M
$1.1B
Total Assets
AMRX
AMRX
RES
RES
Q1 26
$3.5B
Q4 25
$3.7B
$1.5B
Q3 25
$3.6B
$1.5B
Q2 25
$3.4B
$1.5B
Q1 25
$3.4B
$1.3B
Q4 24
$3.5B
$1.4B
Q3 24
$3.5B
$1.3B
Q2 24
$3.5B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
RES
RES
Operating Cash FlowLast quarter
$61.9M
Free Cash FlowOCF − Capex
$31.2M
FCF MarginFCF / Revenue
7.3%
Capex IntensityCapex / Revenue
7.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$52.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
RES
RES
Q1 26
Q4 25
$130.3M
$61.9M
Q3 25
$118.5M
$46.5M
Q2 25
$83.8M
$53.1M
Q1 25
$7.4M
$39.9M
Q4 24
$118.1M
$94.2M
Q3 24
$141.8M
$70.7M
Q2 24
$39.7M
$127.9M
Free Cash Flow
AMRX
AMRX
RES
RES
Q1 26
Q4 25
$108.5M
$31.2M
Q3 25
$106.2M
$4.1M
Q2 25
$61.0M
$10.0M
Q1 25
$-5.8M
$7.6M
Q4 24
$102.9M
$53.7M
Q3 24
$124.8M
$19.1M
Q2 24
$29.0M
$52.9M
FCF Margin
AMRX
AMRX
RES
RES
Q1 26
Q4 25
13.3%
7.3%
Q3 25
13.5%
0.9%
Q2 25
8.4%
2.4%
Q1 25
-0.8%
2.3%
Q4 24
14.1%
16.0%
Q3 24
17.8%
5.6%
Q2 24
4.1%
14.5%
Capex Intensity
AMRX
AMRX
RES
RES
Q1 26
Q4 25
2.7%
7.2%
Q3 25
1.6%
9.5%
Q2 25
3.2%
10.2%
Q1 25
1.9%
9.7%
Q4 24
2.1%
12.1%
Q3 24
2.4%
15.3%
Q2 24
1.5%
20.6%
Cash Conversion
AMRX
AMRX
RES
RES
Q1 26
Q4 25
3.72×
Q3 25
50.00×
3.59×
Q2 25
3.74×
5.23×
Q1 25
0.61×
3.31×
Q4 24
7.38×
Q3 24
3.76×
Q2 24
6.62×
3.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRX
AMRX

Segment breakdown not available.

RES
RES

Technical Service$405.2M95%
Other$8.8M2%
Nitrogen$6.6M2%

Related Comparisons